DEALS: Deals Table headline


Schering, Celera ink $365M deal


DEALS

WHO

WITH

WHAT

SCOOP

Schering

Celera Genomics

$365M licensing deal

Schering has acquired Celera Genomics' cathepsin S inhibitor small molecule drug program for the treatment of autoimmune diseases.

Pfizer

Bayer Pharmaceuticals

Licensing deal

The companies have entered into an agreement granting Pfizer exclusive worldwide rights to Bayer's DGAT-1 inhibitors, a class of compounds that modify lipid metabolism.

PTC Therapeutics

CV Therapeutics

Research collaboration

The companies will work on development of orally bioavailable small molecules through the application of PTC's GEMS (Gene Expression Modulation by Small-Molecules) technology.

U.S. Government

Human Genome Sciences

$165M purchase

U.S. Government has exercised its option to purchase 20,000 treatment courses of ABthrax for the Strategic National Stockpile from HGS.

Discovery Partners International

Galapagos

$5.4M purchase agreement

All the drug discovery service operations of DPI will be transfered to Galapagos.

Novartis

Intercell

$37.86M marketing deal

Novartis has bought the rights to market IC51, a late-stage drug for the prevention of Japanese Encephalitis virus infections from Austrian biotech firm Intercell.

PRA International

Pharma Bio-Research

€85M acquisition

Pharma Bio-Research is a private early-phase clinical development company based in the Netherlands.

Nicholas Piramal

Pfizer

Acquisition

Nicholas Piramal has acquired one of Pfizer's plants in Britain. The deal includes a supply agreement until November 2011 totaling potential revenues of above $350M.

Nutra Pharma

ReceptoPharm

Merger

ReceptoPharm has signed a letter of intent to be fully acquired by Nutra Pharma, a biotech that is developing drugs for HIV and MS.

PharmAthene

SIGA

Merger

The company will operate under the "PharmAthene" name and focus on biodefense.